Related by context. All words. (Click for frequent words.) 84 Antihypertensive 76 Attack Trial ALLHAT 74 Prevent Heart 68 Carotid Revascularization Endarterectomy vs. 67 Cholesterol Levels SPARCL 67 Platelet Inhibition 67 Aggressive Reduction 67 Trandolapril 67 SPARCL 67 ALLHAT 67 Thiazolidinediones 67 Acute Myocardial Infarction 66 Nesiritide 66 Fondaparinux 66 Intervention Effectiveness 66 Prospective Randomized 66 Venous Thromboembolism 66 Cardiovascular Outcomes 66 Randomized Double blind 66 Cardiovascular Risk 65 Atorvastatin Evaluation 65 Unstable Angina 65 Myocardial Ischemia 65 Septic Shock 65 See CLINICAL PHARMACOLOGY 65 prospective multicentre 65 Cardiac Resynchronization 65 Adenoma Prevention 65 Prostate AdenoCarcinoma Treatment 65 RE LY 65 Stent Thrombosis 64 Dialysis Outcomes 64 Rosuvastatin 64 Celecoxib APC trial 64 Controlled Trial 64 Hemodialysis Patients 64 Demonstrates Efficacy 64 J Am Coll 64 Hypotension 64 Patients Undergoing 64 Levels Linked 64 Cardiovascular Events 64 Tiotropium 64 Thromboembolism 64 Antiplatelet 64 ExTRACT TIMI 64 Carotid Stenting 64 Drug Prevents 64 Intervention Effectiveness CATIE 64 Non Alcoholic Steatohepatitis 63 Patient Outcomes 63 Acute Coronary Syndromes 63 Anticoagulation 63 rosuvastatin Crestor 63 Candesartan 63 Postmenopausal Women 63 Deforolimus 63 Unfractionated Heparin 63 ATACAND 63 Intervention Trial GAIT 63 Val HeFT 63 INTERHEART study 63 Aliskiren 63 Meta Analysis 63 Microalbuminuria 63 C Reactive Protein 63 Cardiotoxicity 63 Ischemic Stroke 63 angiotensin II receptor blockers 63 Recurrent Stroke 63 Systematic Review 63 Antitumor Activity 63 Endothelial Function 63 Randomized Controlled Trials 63 Severe Sepsis 63 Chronic Heart Failure 63 Oral Fingolimod 63 Tumor Response 63 Nonalcoholic Fatty Liver Disease 63 Surgical Treatment 63 Bucindolol 63 fluvastatin 63 Renal Artery 63 Recurrent Breast Cancer 63 hypercholesterolaemia 63 Patients Treated With 63 Investigational Compound 63 Left Ventricular Dysfunction 63 Fungal Infections 63 Multiethnic Study 63 Subgroup Analysis 63 BARI 2D 63 Occlusive Disease 63 candesartan cilexetil 63 RE LY ® 63 Effectively Treats 63 Bivalirudin 63 EEG abnormalities 62 Patients Receiving 62 Peripheral Arterial 62 HORIZONS AMI 62 Thromboembolic 62 Controlled Study 62 Coronary Artery Calcium 62 Pooled Analysis 62 Fracture Risk 62 Valsartan 62 ACCOMPLISH 62 CARE HF 62 STRIDE PD 62 R rosiglitazone maleate 62 Fibrates 62 Treating Chronic 62 Cardiac Allograft Rejection 62 Osteoporosis Drugs 62 AIM HIGH 62 #-# Full Text 62 β blockers 62 Resistant Hypertension 62 Clinical Antipsychotic Trials 62 Invasive Breast Cancer 62 Non Alcoholic Fatty 62 CLARITY TIMI 62 Intervention Trial 62 Pulmonary Arterial Hypertension 62 Prostate Lung Colorectal 62 venous thromboembolic disease 62 APPRAISE 62 Intracerebral 62 Heart Failure Trial 62 Cyclooxygenase 2 62 Allergic Rhinitis 62 aspirin clopidogrel 62 ARBITER 6 62 number NCT# ClinicalTrials.gov 62 Aortic Stenosis 62 Acute Liver Failure 62 Stenting Trial CREST 62 Pivotal Trial 62 Inflammatory Markers 62 Lowers Risk 62 Postmarketing 62 Evaluation WISE 62 Heart Failure Patients 62 ONTARGET 62 AVAPRO 62 Phase III Clinical Trial 62 AVERROES 62 Ischemic 62 Non inferiority 62 Suicidality 62 ST Segment Elevation 62 Ezetimibe 62 Ranolazine 62 Overactive Bladder 62 Breast Cancer Recurrence 61 Risk Stratification 61 Poorly Controlled 61 Randomized Evaluation 61 Glucosamine Chondroitin Arthritis 61 Coronary Angiography 61 Long Term Efficacy 61 Sipuleucel T 61 Clinical Efficacy 61 Albuminuria 61 Cervical Dysplasia 61 Molecular Basis 61 angiotensin converting enzyme inhibitors 61 ACE Inhibitors 61 TIMI Study Group 61 Acute Exacerbations 61 Teriflunomide 61 Percutaneous Coronary Intervention 61 Clinical Trial Results 61 Acute Decompensated Heart Failure 61 Aneurysm Repair 61 Rheumatoid Arthritis Patients 61 Prostate Cancer Recurrence 61 antihypertensive therapy 61 Cardiol 61 Primary Hypercholesterolemia 61 Statistically Significant 61 Gastric Cancer 61 Clinical Outcome 61 Randomized Study 61 INTEGRILIN R 61 Insulin Sensitivity 61 Clinical Outcomes Utilizing Revascularization 61 Multicenter 61 Randomized Phase II 61 Outpatient Setting 61 Bone Fracture 61 Phase 2b Clinical Trial 61 Coronary Artery Bypass Graft 61 Warfarin Coumadin 61 Therapy Reduces 61 Diabetic Nephropathy 61 Reperfusion Injury 61 Benign Prostatic Hyperplasia 61 HYVET 61 Predisposition 61 Artery Disease 61 Novel Oral 61 Increased Mortality 61 Clinical Practice Guideline 61 Patency 61 Relapsed Multiple Myeloma 61 Clinical Evaluation 61 Prospective Multicenter 61 Acute Ischemic Stroke 61 Orthostatic Hypotension 61 Pharmacokinetic 61 Aprotinin 61 Cholesterol Lowering Drug 61 Hypercholesterolemia 61 subanalysis 61 Randomized Clinical Trial 61 Arch Neurol 61 Tigecycline 61 Multicenter Study 61 Double Blind Placebo 61 Progressive Multifocal Leukoencephalopathy 61 Refractory Hodgkin Lymphoma 61 Acute Myocardial 61 riociguat 61 Phase 2a Clinical Trial 61 Decompensated Heart Failure 61 trials RCTs 61 Drug Shows Promise 61 Antifungals 61 serum lipids 61 CAPRIE 61 Anticancer Drugs 61 JAK Inhibitor 61 Shows Efficacy 61 Intracerebral Hemorrhage 61 Stop Hypertension DASH 61 Mortality Risk 61 Hospital Acquired Pneumonia 61 Adjuvant Chemotherapy 60 RIO Lipids 60 IMPACT DCM 60 multicenter multinational 60 Meets Primary Endpoint 60 Complications Trial 60 Telmisartan 60 Multicenter Phase 60 International Verapamil SR 60 NIASPAN 60 Phase 2b Study 60 Severe Asthma 60 Proton Pump Inhibitors 60 RE LY trial 60 Refractory Angina 60 Liver Failure 60 Statin Drugs 60 Thrombolysis 60 Genetic Markers 60 Clinical Trial Evaluating 60 INSPIRE Trial Phase III 60 Rosiglitazone Evaluated 60 HIV HCV coinfected 60 ACUITY trial 60 myopathy rhabdomyolysis 60 Demonstrate Significant 60 Preterm Delivery 60 Carvedilol 60 Aggressive Drug Evaluation 60 Stop Hypertension 60 ACCORD Lipid 60 Reduces Mortality 60 Histopathological 60 Meta analyzes 60 Sleep Disturbances 60 Osteoporosis Drug 60 Organ Rejection 60 Aggressive Prostate Cancer 60 MEND CABG 60 ACE Inhibitor 60 Cognitive Impairment 60 Dasatinib 60 Iron Deficiency 60 Anemia Drug 60 Denufosol 60 Novel Antibiotic 60 sunitinib Sutent 60 thienopyridines 60 Reduce Cardiovascular 60 Prognostic Factors 60 Relapsing Remitting Multiple Sclerosis 60 Anticoagulants 60 Hormone Refractory Prostate Cancer 60 Improves Survival 60 meta regression 60 Prostate Cancer Prevention 60 SCD HeFT 60 Multi Ethnic Study 60 Chemotherapeutic Agents 60 Known hypersensitivity 60 Inhaled Corticosteroids 60 hematological parameters 60 Bone Fractures 60 elevated LDL cholesterol 60 Digital Mammographic Imaging 60 NATRECOR ® 60 Ovarian Cancer Screening 60 paroxetine Paxil 60 Combination Treatment 60 Myocardial Infarction 60 undergoing Percutaneous Coronary 60 CHAMPION PCI 60 ziprasidone Geodon 60 Carotid Endarterectomy 60 Treatment Outcome 60 Enoxaparin 60 Genetic Marker 60 antiplatelet drugs 60 HCV SPRINT 60 Hypertensive Patients 60 FASLODEX 60 Preclinical Study 60 Kidney Transplant Patients 60 Avandia Actos 60 N Engl J 60 Myocardial Infarction Study 60 Investigational Treatment 60 Enzastaurin 60 Renal Impairment 60 Irbesartan 60 Bone Mineral Density 60 Appears Safe 60 Postmenopausal 60 Diabetic Neuropathy 60 aldosterone antagonists 60 Complicated Skin 60 oral antidiabetic medication 60 Peptic Ulcer 60 ischemic complications 60 Proteinuria 60 Prognostic Value 60 chronic thromboembolic pulmonary 60 Stress Induced 60 Liver Injury 60 Hormone Therapy 60 Celecoxib 60 Am J Clin 60 Beta Blocker 60 Intracranial Aneurysms 60 Enlarged Prostate 60 fosbretabulin 60 Bone Metastases 60 Shows Promise Against 60 Cancer Incidence Mortality 60 ACTEMRA TM 60 Stenting 60 Study Showed 60 Eur J 60 Combination REOLYSIN R 60 Antipsychotic 60 Clostridium difficile Infection 60 Atopic Dermatitis 60 patients undergoing percutaneous 60 Homocysteine 60 Diabetes Interventions 60 candesartan 60 Daptomycin 60 Angiographic 60 Bare Metal Stent 60 Venous Thrombosis 60 Epilepsy Drug 60 induce orthostatic hypotension 60 Vildagliptin 60 Paliperidone ER 60 Pharmacologic 60 Renal Cell Carcinoma 59 Lp PLA 2 59 Kidney Failure 59 Contraindications 59 pioglitazone hydrochloride 59 Coronary Revascularization 59 alfuzosin 59 MADIT CRT 59 Hip Fractures 59 benazepril 59 Metastatic Prostate Cancer 59 Periodontal Disease 59 Lipoprotein 59 Cognitive Function 59 Prostate Cancer Patients 59 prospective observational cohort 59 Newly Diagnosed Multiple Myeloma 59 Prospective Randomized Trial 59 Captopril 59 Mg Uk 59 Chronic Constipation 59 Phase IIb Trial 59 selenium supplementation 59 dysglycemia 59 Mg Usa 59 Ambulatory Blood Pressure 59 lumiracoxib 59 Malignant Glioma 59 Therapeutic Effects 59 Celebrex celecoxib 59 leukotriene receptor antagonists 59 BRIM3 59 HMG CoA reductase inhibitors 59 BOLDER II 59 NDA Submission 59 unfractionated heparin UFH 59 anticoagulant warfarin 59 Osteoarthritis Patients 59 Prehypertension 59 RECORD1 59 Neoadjuvant Chemotherapy 59 Attenuates 59 Hyperuricemia 59 Chronic Bronchitis 59 See WARNINGS 59 subgroup analyzes 59 Stent Restenosis 59 Demonstrated Significant 59 Antiplatelet Therapy 59 RE MODEL 59 angiotensin receptor blockers 59 Drug Coated Stents 59 Placebo Controlled Trial 59 ARCOXIA 59 Nilotinib 59 Investigational Drug 59 Advanced Melanoma 59 undergoing elective percutaneous 59 REALITY Trial 59 EDARBI 59 Fulvestrant 59 Radiofrequency Ablation 59 Kidney Function 59 Erythropoietic therapies may 59 Uric Acid 59 BYSTOLIC 59 SORT OUT III 59 Nebulized 59 lipoprotein Lp 59 Prolongs Survival 59 Skeletal Muscle 59 ritonavir boosted 59 Combo Therapy 59 Improves Outcomes 59 CALERIE 59 Blood Thinner 59 aripiprazole Abilify 59 multicenter randomized clinical 59 oral dual endothelin 59 longitudinal cohort study 59 Fluorouracil 59 Therapeutic Efficacy 59 Ovarian PLCO Cancer 59 Anthracycline 59 multicenter randomized controlled 59 Menopausal Symptoms 59 Phase III AFFIRM 59 Skin Lesions 59 ACTOS ® 59 Left Ventricular 59 Low Dose 59 CHARISMA trial 59 Stop Hypertension diet 59 LDL Cholesterol 59 Prostate Cancer Treatment 59 Medication Errors 59 Rofecoxib 59 AVANDIA 59 Intracranial 59 Diabetic Patients 59 Darapladib 59 INCB# [003] 59 Proves Effective 59 nonrandomized 59 CYP#A# CYP#D# 59 6R BH4 59 Abciximab 59 Multicenter Randomized 59 Atherosclerotic 59 Localized Prostate Cancer 59 Liprotamase 59 CLINICAL PHARMACOLOGY 59 Randomized Double Blind Placebo 59 MERIT ES 59 Restenosis 59 Pharmacodynamics 59 thromboembolic complications 59 Cholesterol Levels 59 Eculizumab 59 pravastatin Pravachol 59 Cancer Recurrence 59 Pain Relievers 59 Coronary Disease 59 Heartburn Drugs 59 HALTS 59 Gene Variation 59 Heterozygous Familial Hypercholesterolemia 59 Catheter Associated 59 non cirrhotic portal 59 Unresectable 59 serum leptin 59 prospective randomized placebo 59 MADIT II 59 Salmeterol 59 plasma lipid 59 Cardiometabolic 59 Demonstrates Positive 59 Bosutinib 59 Lipid Lowering 59 Prophylactic Treatment 59 atherothrombotic disease 59 ® pioglitazone HCl 59 Telithromycin 59 Breast Cancer Risk 59 moderate hepatic impairment 59 Hyperlipidemia 59 Shows Promising 59 Critically Ill Patients 59 tiagabine 59 Obese Patients 59 Weight Loss Supplement 59 Cardiovascular Risk Factors 59 Blood Pressure Drugs 59 Antiepileptic Drugs 59 Infarction 59 cilostazol 59 BERKELEY CA UroToday.com 59 Oral Calcitonin 59 #th Interscience Conference 59 Dyslipidemia 59 Acute Stroke 59 Lung Cancer Risk 59 eprotirome 59 Autoimmune Diseases 59 Pharmacogenetic 59 Methylnaltrexone 59 Eluting Stent 59 Clinical Practice Guidelines 59 lipid lowering agents 59 acute humoral rejection 59 randomized multicenter trial 59 Pharmacokinetic PK 59 Statin Therapy 59 Autologous Stem Cell Transplantation 59 EURIDIS 59 NIDDM 59 Ischaemic 59 Reduced Risk 59 Nicotine Vaccine 59 Randomized controlled 59 STEP BD 59 MERLIN TIMI 59 Events MACE 59 Confirms Efficacy 59 VADT 59 Adverse Effects 59 #:#-#,# CrossRef Medline [002] 59 Paxil paroxetine 59 Hertzel Gerstein 59 Sustained Efficacy 59 Atypical Hemolytic Uremic Syndrome 59 Antidepressant Use 59 Microplasmin 59 Pravastatin 59 Catheterization 59 phase IIIb 59 ARIXTRA 59 Hepatotoxicity 59 Predict Risk 59 Acute Pancreatitis 59 NHANES III 59 Thrombotic 58 II Clinical Trial 58 Muraglitazar 58 Hematological Cancers 58 NICE SUGAR 58 STRATEGY FOR AN OPEN 58 Inhaled Nitric Oxide 58 Pediatric Patients 58 Antidepressant Drug 58 leiomyomas 58 Vascular Disease 58 Apixaban 58 Oxidized LDL 58 Knee Osteoarthritis 58 TRITON TIMI 58 Fixed Dose 58 Observational Study 58 diuretics beta blockers 58 TRA 2P 58 Multicenter Trial 58 prospectively stratified 58 Metastatic Renal Cell Carcinoma 58 Renal Function 58 relapsed MM 58 homocysteine concentrations 58 glycated hemoglobin HbA1c 58 lipid abnormalities 58 GISSI HF 58 icatibant 58 COREG 58 Relapsing Multiple Sclerosis 58 Cardiovascular Disease Risk 58 Syncria R 58 Pivotal Phase III 58 Cilostazol 58 Primary endpoints 58 Coronary CTA 58 Drug Candidate 58 Stroke Risk 58 Impaired Glucose Tolerance 58 chromium supplementation 58 Adenoma 58 Secondary Hyperparathyroidism 58 Phase 2b Trial 58 Aceon 58 Treatment Reduces 58 Arch Intern Med 58 Liver Damage 58 Renal Anemia 58 Sustained Release 58 Zarnestra 58 AA Amyloidosis 58 Systolic Blood Pressure 58 postmenopausal hormone therapy 58 angiotensin receptor blocker ARB 58 Embolic Protection Device 58 Slow Progression 58 Subgroup analysis 58 Single Dose 58 ECASS 58 RIO Diabetes 58 Dietary Approaches 58 Pivotal Clinical Trial 58 Tolvaptan 58 Treatment Shows Promise 58 Epilepsy Drugs 58 Study Evaluating 58 Metabolic Disease 58 Corticosteroid 58 fluvastatin Lescol 58 Disease Severity 58 Effective Treatments 58 Acne Drug 58 #:#-# [035] 58 Myocardial 58 antiplatelet medications 58 CYP#A# substrate 58 Glycemic Control 58 HER2 Positive Breast Cancer 58 Genetic Variation 58 SIMCOR 58 Dual Antiplatelet Therapy 58 polyarticular 58 #:#-# [031] 58 Nasal Sprays 58 Nicotine Addiction 58 MAGE A3 ASCI 58 Guideline Update 58 PLX STROKE targeting 58 Immunologic 58 Lowers Blood Pressure 58 CYT# potent vascular disrupting 58 Rosiglitazone 58 exploratory endpoints 58 Often Misdiagnosed 58 multicentre randomized 58 Randomised 58 Diabetes ACCORD 58 Comorbidities 58 First Patient Enrolled 58 Differential Diagnosis 58 Lung Injury 58 Clin Chem 58 Nymox NX 58 Diabetic Kidney Disease 58 Phase III Trial 58 Neoplasms 58 inhibit platelet function 58 Breast Cancer Metastasis 58 novel VDA molecule 58 MEVACOR 58 Hospitalized Patients 58 Moxifloxacin 58 Anti Tumor 58 Golimumab 58 Cognitive Decline 58 Novel Mechanism 58 Stop Hypertension DASH diet 58 Disease Progression 58 Epidermal Growth Factor Receptor 58 Sudden Cardiac Death 58 recurrent glioblastoma multiforme 58 total cholesterol triglycerides 58 Insulin Resistance 58 thromboembolic disease 58 Crit Rev 58 Brain Shrinkage 58 Pharmacodynamic 58 Statin Use 58 Peginterferon Alfa 2a 58 Atherosclerosis MESA 58 Women Ischemia Syndrome 58 Rilonacept 58 Calcium Supplements 58 Hematologic 58 Demonstrates Sustained 58 valsartan Diovan 58 BENICAR HCT 58 Gene Mutation 58 Gentium Announces 58 Olmesartan 58 multicentre randomized controlled 58 Prognostic Significance 58 #:#-# [007] 58 Depressive Symptoms 58 macrovascular events 58 Chronic Liver Disease 58 anaphylactic reactions bronchospasm 58 Prolongs Life 58 Postmenopausal Hormone Therapy 58 Oral Anticoagulants 58 ZOLINZA 58 Scandinavian Simvastatin Survival 58 Achieves Primary Endpoint 58 Atomoxetine 58 gabapentin Neurontin 58 Treat Heart Failure 58 Randomized Controlled Trial 58 Rotavirus Vaccine 58 canakinumab 58 Medication Adherence 58 Left Ventricular Hypertrophy 58 Ventricular Arrhythmias 58 J Clin 58 Randomized Phase 58 Thyroid Hormone 58 #:#-# [023] 58 Infarct 58 Anti Inflammatory Drug 58 ORAL Sync 58 postoperative atrial fibrillation 58 Medidur TM FA 58 Stress Incontinence 58 Atherosclerosis 58 CT Angiography 58 Tipranavir 58 Phase III multicenter 58 Colorectal Adenomas 58 acute myocardial infarction MI 58 Solid Tumors 58 prostate TURP 58 PROactive study 58 ANN INTERN MED 58 Echocardiographic 58 Folic Acid Supplements 58 Anticoagulant 58 Bisphosphonate 58 sulodexide 58 Hormone Replacement 58 Hyperparathyroidism 58 Hepatic 58 mixed hyperlipidemia 58 Tumor Progression 58 Racial Differences 58 Chronic HCV 58 elevated triglycerides 58 Anti Depressant 58 Protein Linked 58 AVOREN 58 Montelukast 58 Well Tolerated 58 Tanespimycin 58 prospective observational studies 58 PRADAXA 58 recurrent venous thromboembolism 58 MEK Inhibitor 58 Pioglitazone 58 intensive statin therapy 58 Esophagitis 58 Hemolysis 58 Improve Outcomes 58 Cholesterol Drug 58 HDL Cholesterol 58 Phase IIb Clinical Trial 58 Dose Escalation 58 valvular heart 58 CYPHER R Sirolimus Eluting 58 beta carotene supplementation 58 Improve Survival 58 carotid artery stenting CAS 58 HF ACTION 58 Adalimumab 58 Prevent Breast Cancer 58 ramipril Altace 58 placebo controlled studies 58 Rivaroxaban 58 metastatic castration resistant 58 Intervention Trial Evaluating 58 plasma pharmacokinetics 58 Castration Resistant Prostate Cancer 58 serum triglycerides 57 Antitumor 57 cerivastatin 57 BZA CE 57 Heart Failure Therapies 57 Acute Coronary Syndrome 57 Metabolic Endocrinology 57 Virus Linked 57 Pulmonary Embolism 57 lipid lowering drugs 57 severe hypercholesterolemia 57 cardiovascular morbidity 57 chlorthalidone 57 Analytical Tool 57 Telik Announces 57 Monopril 57 renoprotective 57 5 Fluorouracil 57 NATRECOR R 57 Arterial Disease 57 nicardipine 57 Adjuvant Treatment 57 Temsirolimus 57 Crestor rosuvastatin 57 dyslipidemia hypertension diabetes 57 rosuvastatin #mg 57 Drug Fails 57 GISSI 57 Lp PLA2 57 Placebo controlled 57 morphometric vertebral fractures 57 risperidone Risperdal 57 lowers triglycerides 57 PRoFESS 57 Bladder Cancer 57 FDA Okays 57 LAB CGRP 57 atorvastatin Lipitor 57 Prevent Stroke 57 Duodenal 57 angiotensin converting enzyme inhibitor 57 HDAC Inhibitor 57 Dose Response 57 Randomized Double Blind 57 glitazones 57 Clinical Trial Data 57 Gene Variants 57 angiotensin receptor blockers ARBs 57 Nonalcoholic Steatohepatitis 57 Schizophrenia Treatment 57 Eye Disease 57 pharmacodynamic effects 57 channel blocker amlodipine 57 PCI ExTRACT TIMI 57 CATIE AD 57 inflammatory biomarkers 57 sorafenib Nexavar 57 Sapacitabine 57 Clot Busting 57 Prostate Cancer Progression 57 Gheorghiade 57 PICSO ® 57 EXPAREL ™ 57 Polyneuropathy 57 Dabigatran 57 acarbose 57 Randomized Trials 57 Am J Geriatr 57 ASTEROID 57 Anti Clotting Drug 57 Cardiac Arrhythmias 57 Adiposity 57 Pivotal Phase 57 HeFH 57 dual endothelin receptor antagonist 57 NAVISTAR R 57 atherogenic dyslipidemia 57 Study Casts Doubt 57 Increases Risk 57 Tocilizumab 57 Novel Inhibitor 57 coronary revascularizations 57 SUTENT ® 57 prospective randomized multicenter 57 IL# PE#QQR 57 CombAT 57 clazosentan 57 Angiotensin Converting Enzyme 57 Adverse Event 57 CIMZIA TM certolizumab pegol 57 Cholesterol Drugs 57 landmark ATHENA 57 Diabetic Foot Ulcer 57 Initiates Phase III 57 Degarelix 57 Neurodegenerative 57 Circulating Tumor Cells 57 Thyroid Function 57 Chicago Multidisciplinary Symposium 57 Menopausal Women 57 Amniotic Fluid 57 glomerular filtration 57 Abbott Trilipix 57 R lenalidomide 57 Edge STudy 57 Pediatric Asthma 57 Tumor Growth 57 antidepressants fluoxetine 57 hypervascular tumors 57 Randomized Clinical Trials 57 Aurora Kinase 57 Alpha Tocopherol Beta Carotene 57 Systolic Hypertension 57 Renal Cancer 57 #:#-# [029] 57 VICTOR E3 57 EuroIntervention 57 Galectin 3 57 Protein Expression 57 Acute Pain 57 Glucosamine chondroitin Arthritis 57 Lowers Cholesterol 57 Radical Prostatectomy 57 SYNTAX 57 Survival Benefit 57 Gilead Viread 57 Treatment Naive HIV 57 Analgesic 57 Pafuramidine 57 Critical Limb Ischemia CLI 57 BEXXAR Therapeutic Regimen 57 Cystatin C 57 Paroxysmal Nocturnal Hemoglobinuria PNH 57 Diabetes Complications 57 Protease Inhibitors 57 Maleate 57 Viral Infections 57 bronchial hyperresponsiveness 57 Pivotal Study 57 EVEREST II 57 Dietary Modification Trial 57 Coronary Arteries 57 Lipid Levels 57 Portal Hypertension 57 Adjunctive 57 EchoCRT 57 Naive Patients 57 Main Outcome Measure 57 Topiramate 57 Vertebral Fractures 57 Minimally Invasive Treatment 57 lipoprotein levels 57 Drug Induced 57 Gender Differences 57 Afatinib 57 Pneumococcal Vaccine 57 irbesartan 57 HORIZONS AMI trial 57 Premature Infants 57 Excessive Sweating 57 Trial PCPT 57 Study Shows Promise 57 bezafibrate 57 Reperfusion 57 worsening thrombocytopenia 57 rFVIIa 57 Postmenopausal Osteoporosis 57 Triglyceride 57 Asthma Treatment 57 prospective nonrandomized 57 aldosterone antagonist 57 Therapeutic Potential 57 Observational studies 57 non valvular atrial 57 Bipolar Mania 57 direct thrombin inhibitors 57 Vaginal Gel 57 stable angina 57 NCCTG N# 57 pharmacodynamic parameters 57 Blood Pressure Monitoring 57 Phase Ib Clinical Trial 57 Drug Combo 57 Warner Chilcott Actonel 57 Dementia Related Psychosis 57 Successfully Treated 57 Percutaneous Tibial Nerve Stimulation 57 Neuroprotective 57 CALGB # [001] 57 Diagnostic Accuracy 57 Patient Enrollment 57 Pemetrexed 57 Late Breaker 57 Ventricular Tachycardia